Reckitt Benckiser Group plc (3RBB.F)
- Previous Close
11.60 - Open
11.40 - Bid 11.40 x 60000
- Ask 11.70 x 60000
- Day's Range
11.40 - 11.40 - 52 Week Range
9.55 - 12.70 - Volume
716 - Avg. Volume
11 - Market Cap (intraday)
39.221B - Beta (5Y Monthly) 0.12
- PE Ratio (TTM)
23.75 - EPS (TTM)
0.48 - Earnings Date Jul 24, 2025
- Forward Dividend & Yield 0.47 (4.11%)
- Ex-Dividend Date Apr 11, 2025
- 1y Target Est
--
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, and Strepsils names. It also provides personal care products under Clearasil and Veet brand names; vitamins, minerals, and supplements under Airborne, Movefree, and neuriva names; and disinfectant products under the Finish, Harpic, and Lysol brands. In addition, the company offers nutritious complementary foods and milk formulas for infant and young children under the Enfamil and Nutramigen brands. Reckitt Benckiser Group plc was founded in 1819 and is headquartered in Slough, the United Kingdom.
www.reckitt.com37,900
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 3RBB.F
View MorePerformance Overview: 3RBB.F
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 3RBB.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 3RBB.F
View MoreValuation Measures
Market Cap
39.16B
Enterprise Value
48.47B
Trailing P/E
23.71
Forward P/E
14.81
PEG Ratio (5yr expected)
1.27
Price/Sales (ttm)
2.39
Price/Book (mrq)
4.91
Enterprise Value/Revenue
2.90
Enterprise Value/EBITDA
13.89
Financial Highlights
Profitability and Income Statement
Profit Margin
10.06%
Return on Assets (ttm)
8.22%
Return on Equity (ttm)
18.86%
Revenue (ttm)
14.17B
Net Income Avi to Common (ttm)
1.43B
Diluted EPS (ttm)
0.48
Balance Sheet and Cash Flow
Total Cash (mrq)
880M
Total Debt/Equity (mrq)
131.41%
Levered Free Cash Flow (ttm)
2.11B